LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multiprotein complex that has bipartite DNA binding through ...

Q2 2025 Earnings Call Transcript August 4, 2025 Syndax Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...